Fleury SA operates within the Medical laboratories sector. In addition to historical fundamental analyses, the complete report available to purchase compares Fleury SA with three other pharmaceutical manufacturers in Latin America: Instituto Hermes Pardini SA (2020 sales of 1.49 billion Brazilian Reals [US$266.07 million] of which 100% was auxiliary diagnostic support services), Ouro Fino Saude Animal Participacoes SA (730.11 million Brazilian Reals [US$130.02 million] of which 74% was Production Animals), and Hypera SA (4.09 billion Brazilian Reals [US$728.19 million] ).

Sales Analysis. During the year ended December of 2020, sales at Fleury SA were 2.97 billion Brazilian Reals (US$529.22 million). This is an increase of 2.3% versus 2019, when the company's sales were 2.91 billion Brazilian Reals. This was the fifth consecutive year of sales increases at Fleury SA (and since 2015, sales have increased a total of 57%). Sales of Integrated Medicine saw an increase that was more than double the company's growth rate: sales were up 15.3% in 2020, from 467.62 million Brazilian Reals to 538.93 million Brazilian Reals. Not all segments of Fleury SA experienced an increase in sales in 2020: sales of Diagnostic Medicine fell 0.2% to 2.43 billion Brazilian Reals.